$5,999.00
In Stock
Lumakras is an antineoplastic drug. A first-in-class KRAS G12C inhibitor.
Lumykras as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation that has progressed after at least one prior systemic therapy.
About Non-Small Cell Lung Cancer and the KRAS G12C Mutation
Lung cancer is the leading cause of cancer death, accounting for more deaths than colon cancer and breast cancer combined5. Globally, non-small cell lung cancer accounts for approximately 85%6 of the 2.2 million5.7 new lung cancer diagnoses each year.
In Russia, lung cancer is the most common malignant neoplasm in the male population of Russia (16.4%) and the third most common (9.7%) in the incidence of malignant neoplasms in both sexes. 9. About 48 thousand new cases of lung cancer are diagnosed in Russia annually. 8.
The KRAS G12C mutation type is one of the most common KRAS mutations in NSCLC. 9 It occurs in 13% of patients. 10. Overall survival in NSCLC is currently improving, but remains low for patients in the late stages of the disease, and 5-year survival in patients with metastases is only 7%. 10.
Active ingredient: sotorasib
Prescription drug.
The drug is delivered from Germany.
